title: Hepatosplenic T-cell lymphoma and TNF-α inhibitors.
authors.forename: Jenny Vu
authors.initials: JV
authors.lastname: Pozadzides
authors.forename: Barbara
authors.initials: B
authors.lastname: Pro
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D000069285:Infliximab; D008113:Liver Neoplasms / Q000401:mortality / Q000503:physiopathology* / Q000628:therapy*; D016399:Lymphoma, T-Cell / Q000401:mortality / Q000503:physiopathology* / Q000628:therapy*; D008297:Male; D013160:Splenic Neoplasms / Q000401:mortality / Q000503:physiopathology* / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab